APPLICATIONS PUBLISHED 8 DECEMBER 2004
Published: 2-Aug-2005
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Modified release oral pharmaceutical compsn
Ranbaxy Laboratories 1482910*
Dispersed solid-containing complex carbohydrate
Carrington Laboratories 1482911*
Naltrexone hydroxhloride compsns
Euro-Celtique 1482912*
A system for the controlled release of active ingredients
Jagotec 1482913*
Implantable drug delivery system
Alcon 1482914*
Therapeutic system for the controlled release of active ingredients
Jagotec 1482915*
Schwann cell and phosphodiesterase inhibitors based therapy
University of Miami 1482916*
Compsn comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GW Pharma 1482917*
Utilisation of ubiquinones for influencing the effect of histamine
MSE Pharmaceutika 1482918*
Pharmaceutical compsn that is used to control blood glucose in patients with type 2 diabetes
Laboratoires Silanes 1482919*
N-acyl-phosphatidyl-ethanolamines and.or mixtures of N-acyl-ethanolamines with phosphatidic acids
Hunza di Pistolesi Elvira 1482920*
Methods of treating attention deficiency/hyperactivity disorder (ADHD)
Cypress Bioscience 1482921*
Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
Vitreo-Retinal Technologies 1482922*
Process to prepare semicarbazoles and/or tiosemicarbazones, formulations using cyclodextrins and their derivatives, and products obtained by this process
Universidade Federal de Minas Gerais 1482923*
Cathepsin cysteine protease inhibitors
Merck Frosst Canada; Axys Pharmaceuticals 1482924*
5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropyl)-propionylamino-phtalide and related compounds with progesterone modulating activity for use in fertility control and hormone replacement therapy
Schering 1482925*
Amino-methyl substituted tetracycline compounds
Paratek Pharmaceuticals 1482926*
Method of treating osteoarthritis
Warner-Lambert 1482927*
Mediators of hedgehog signalling pathways, compsns and uses related thereto
Curis 1482928*
Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazole-2-one for producing medicaments that inhibit pancreatic lipase
Aventis Pharma Deutschland 1482929*
Peptide deformylase inhibitors
SmithKline Beecham 1482930*
Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
Transtech Pharma 1482931*
N3 alkylated benzimidazole derivatives as MEK inhibitors
Array Biopharma 1482932*
Potent, simplified derivatives of immunosuppressive agents
The Texas A&M University System 1482933*
2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases
Susio, Rudy 1482934*
Thiazole and oxazole derivatives which modulate PPAR activity
Warner-Lambert 1482935*
Ophthalmic compsn comprising ascomycin
Novartis 1482936*
Novel tyloindicines and related processes, pharmaceutical compsns and methods
Yale University 1482937*
Pharmaceutical compsn of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
ALTANA Pharma 1482938*
Preparation of paroxetine involving novel intermediates
Teva Pharmaceutical Industries 1482939*
Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
Pharmacia 1482940*
Beta-sheet mimetics and compsn and methods relating thereto
Myriad Pharmaceuticals 1482941*
Stabilised pharmaceutical compsns of halofuginone and other quinazolinone derivatives
Collgard Biopharmaceuticals 1482942*
Dosing regimen for gemcitabine HCV therapy
Pharmasset 1482943*
N3 alkylated benzimidazole derivatives as MEK inhibitors
Array Biopharma 1482944*
Crystalline forms of quetiapine hemifumarate
Teva Pharmaceutical Industries 1482945*
Progesterone oral drug delivery system
Watson Pharmaceuticals 1482946*
Extended cycle estrogen and sulphatase inhibiting progestogen contraceptive regimens
Janssen Pharmaceutica 1482947*
Continuous sulphatase inhibiting progestogen hormone replacement therapy
Janssen Pharmaceutica 1482948*
Sulphatase inhibiting progestogen-only contraceptive regimens
Janssen Pharmaceutica 1482949*
A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
Forbes Medi-Tech 1482950*
Alpha-hydroxy-2-methylene-10-norpregnacalciferol and its uses
Wisconsin Alumni Research Foundation 1482951*
Therapeutic and prophylactic treatment of aging and disorders of aging in humans
Rodriguez, Victorio 1482952*
Alpha-substituted heteroarylalkyl phosphonate derivatives
Ilex Products 1482953*
Alpha-substituted arylalkyl phosphonate derivatives
Ilex Products 1482954*
Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
Corixa 1482955*
Targeted drug delivery methods
Vanderbilt University 1482956*
Antibiotic conjugates
Sympore 1482957*
Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine erythrocyte preparations
US Army Medical Research & Materiel Coomand 1482958*
Compsns and methods for treatment of skin disorders
Dermavri 1482959*
Methods and products for oral care
DMI Biosciences 1482960*
Use of soluble FGL2 as an immunosuppressant
Trilium Therapeutics 1482961*
Method of treating TRX mediated diseases
Sloan-Kettering Institute for Cancer Research 1482962*
Controlled modulation of amino acid side chain length of peptide antigens
Board of Regents of the University of Texas System 1482963*
Use of EGFR transactivation in human cancer
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften 1482964*
Method to control tumour progression and invasiveness
Vlaams Interuniversitair Instituut voor Biotechnologie 1482965*
Method and compsn for treating skin wounds with epidermal growth factor
Bio-Click Technologies 1482966*
Pharmaceutical and cosmetic compsns comprising PLGF-1
Geymonat 1482967*
Treatment of type 1 diabetes mellitus using growth hormone antagonist
Pharmacia & Upjohn 1482968*
Purifying process of soluble proteins of the L. obliqua bristles through prothrombin activation; process for a partial determination of the amino acid sequence of the prothrombin activator; process for determining the prothrombin activation of fraction II, N-terminal and internal fragments sequence
Biolab Sanus Farmaceutica; Fundacao de Amparo a Pequisa do Estado de Sao Paolo; Chudzinski-Tavassa, Ana 1482969*
Cancer therapy
Immunaid 1482970*
Strategy for retroviral immunotherapy
Immunaid 1482971*
